Illumina Signs Agreement to Acquire NextBio, Leader in Analyzing and Aggregating Complex Genomic Data

  Illumina Signs Agreement to Acquire NextBio, Leader in Analyzing and
  Aggregating Complex Genomic Data

     Acquisition Will Strengthen Illumina’s Informatics Portfolio, Enable
Accelerated Adoption of Next-Generation Sequencing in Current and New Markets

Business Wire

SAN DIEGO -- October 28, 2013

Illumina, Inc. (NASDAQ:ILMN) today announced it has signed a definitive
agreement to acquire Santa Clara-based NextBio, a leader in clinical and
genomic informatics. NextBio’s powerful big-data platforms aggregate and
analyze large quantities of phenotypic and genomic data for research and
clinical applications. With the addition of NextBio’s platform upon completion
of the acquisition, Illumina will be able to offer customers enterprise level
bioinformatics solutions that accelerate the discovery of new associations
between the human genome and disease, and ultimately, enable the application
of those discoveries within healthcare.

“This agreement with NextBio demonstrates Illumina’s unwavering commitment to
drive the adoption of sequencing in new markets and vastly improve the genomic
information workflow,” saidJay Flatley, President and CEO ofIllumina.
“NextBio enables the classification and aggregation of phenotypic and clinical
data within a single environment and allows analysis of that data at
unprecedented speed and scale. The combination of Illumina’s BaseSpace cloud
computing environment for next-generation sequencing with NextBio’s platform
for integrating patient data will allow us to deliver solutions that
seamlessly integrate the entire workflow from sample to result.”

NextBio’s platform allows customers to quickly compare their experimental
results against thousands of published and private data sets by means of a
unique correlation engine, which pre-computes billions of significant
connections between disparate data elements and helps discover new
associations. NextBio Clinical, which in 2012 passed an independent HIPAA
audit, is designed for seamless integration with existing clinical and
research systems. Backed by highly scalable Software as a Service (SaaS)
enterprise technology, it is capable of analyzing petabytes of data.

NextBio’s database platforms are currently used by researchers and clinicians
in more than 50 commercial and academic institutions. NextBio will be
integrated into Illumina’s newly formed Enterprise Informatics business under
the leadership of Nick Naclerio, SVP of Corporate and Venture Development and
General Manager of Enterprise Informatics. NextBio co-founder Ilya Kupershmidt
and Chief Technology Officer Satnam Alag will continue to provide scientific
and technical leadership as part of the new business unit.

Illumina is confirming its 2013 financial guidance provided on October 21,
2013. The transaction is expected to close by the end of October.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com